Background: Preeclampsia is a pregnancy specific disorder affecting 3-5% of pregnancies
Introduction
Preeclampsia is a pregnancy-specific disorder that presents as new-onset maternal hypertension and proteinuria after 20 weeks of gestation. It affects 3-5% of pregnancies worldwide and is a major cause of maternal and perinatal mortality and morbidity [1] .
Characteristics of preeclampsia include maternal endothelial cell activation and exaggerated inflammation [2, 3] . Preeclampsia is clinically divided into early-onset (<34 weeks of gestation) and late-onset (>34 weeks of gestation) subtypes according to the gestation age of disease onset [4, 5] ; it's becoming increasingly clear that the two subtypes have distinct characteristics [6, 7] . Although the causes of preeclampsia are not yet completely understood, it is well accepted that factors released from the placenta are involved in the pathogenesis of preeclampsia, and that hypoxia and oxidative stress increase placental production of these factors [8] . In addition, preeclampsia is associated with the risk of developing cardiovascular disease later in life [9] , suggesting that preeclampsia and cardiovascular disease may share common risk factors such as those involved in endothelial dysfunction and exaggerated inflammatory responses [10, 11] .
Growth differentiation factor 15 (GDF15), also known as macrophage inhibitory cytokine-1 (MIC-1), is a protein of the transforming growth factor beta (TGF) superfamily that regulates inflammatory and apoptotic pathways in injured tissues and during disease processes [12] . GDF15 is a stress-induced cytokine and associated with hypoxia, inflammation and oxidative stress (review in [13] ), it is also released from endothelial cells after stimulation with pro-inflammatory cytokines [14] . GDF15 has been suggested as a target and biomarker for cardiovascular disease as it plays a cardioprotective role in the adult heart [13, 15] .
GDF15 is highly expressed in the placenta, and comparatively its expression is lower in other tissues such as the kidneys, pancreas, prostate and colon under physiological conditions [16- 4 18] . GDF15 is known to be involved in human embryo development and necessary for the maintenance of pregnancy [19] . GDF15 is also produced by adipocytes in response to oxidative stress [20] , a well-known factor associated with preeclampsia.
In this study, we first determined the serum levels of GDF15 in the third trimester in women presenting with preeclampsia, and investigated whether the changes in GDF15 depend on preeclampsia subtype (early-onset vs late-onset). We then examined whether serum GDF15 is altered at 11-13 weeks of gestation in women who are destined to develop preeclampsia later in pregnancy.
5

Materials and Methods
Study population
Maternal blood samples from preeclamptic women (n=34) at diagnosis in the third trimester and direct gestation-age-matched normotensive pregnant women (n=66) were collected by venipuncture into plain vaccutainer tubes before any clinical treatment. Preeclampsia samples were grouped into subtypes of early-onset (<34 weeks, n=16; direct gestation-age-matched control n=20) and late-onset (>34 weeks, n=18; direct gestation-age-matched control n=46), and their clinical characteristics are summarized in Table 1 . These blood samples were collected at the Department of Obstetrics, Wuxi Maternity and Children's Hospital, Nanjing Medical University, China; the collection was from February 2010 to January 2012.
In addition, a few sera were separately collected in the same facilitate in 2014 from healthy pregnant women at gestation weeks of 11-13 (n=9), 23-27 (n=9) and 33-40 (n=11); these served as representative normal pregnant sera of different trimesters to specifically analyse the GDF15 levels across gestation.
The blood was allowed to clot and centrifuged at 1500 g, the serum was aspirated and stored in aliquots at − 80 °C until use. The study was approved by the Ethics Committee of Wuxi Maternity and Children's Hospital, Nanjing Medical University, China. All samples were obtained with written informed consent.
In addition, in order to investigate whether serum GDF15 levels were altered in the first trimester in women destined to develop preeclampsia, serum samples were also prospectively collected at 11-13 weeks of gestation from women who then proceeded with uncomplicated pregnancies or developed late-onset preeclampsia in the third trimester. These were collected at Royal Prince Alfred Hospital, Sydney, Australia, and participants were originally recruited to a study evaluating an algorithm for predicting the risk of pre-eclampsia in the first trimester [21, 22] . For the current study, singleton pregnant sera representing normal A number of studies suggested that the Preeclampsia was defined as maternal systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥ 90mmHg on two occasions separated by 6 hours, plus proteinuria >300mg in a 24 hour period after 20 weeks of gestation; this was in accordance with the guidelines of the American College of Obstetricians and Gynaecologists [23] . Preeclampsia occurring earlier than 34 weeks of gestation was defined as early-onset, and those presenting after 34 weeks of gestation was defined as late-onset.
Analysis of serum GDF15
Serum levels of GFD15 were measured using a GDF15 ELISA kit (R&D Systems, Minneapolis, MN, USA) following the manufacturer's instructions.
Statistical analysis
Due to differences in sample collection timing (more than 2 years apart), GDF15 levels were analyzed separately for different cohorts. Clinical data were presented as mean and standard deviation (SD). The GDF15 levels were also presented as mean ± SD. The differences in GFD15 levels among the 1 st , 2 nd and 3 rd trimesters were analysed by ANOVA test (KruskalWallis test, because the data were not normally distributed). The differences in GFD15
between preeclampsia (either early-onset or late-onset subtypes) and gestation-age-matched normotensive controls were analysed by Mann-Whitney test as the data were not normally distributed either. All the statistical analyses were performed using the Prism software package (GraphPad Software, Inc, San Diego, CA, USA) and P<0.05 was considered as
Results
Demographic information of the study population
The clinical characteristics of the 34 sera that were collected at the time of preeclampsia presentation and the gestation-age-matched 66 control samples are summarised in Table 1 .
Among the 34 preeclampsia samples, 16 were from early-onset and 18 from late-onset subtypes.
The detailed characteristics of the 11-13 week sera that were collected long before the presentation of preeclampsia were previously published [21, 22] . This current study randomly selected 33 normal and 36 late-onset preeclampsia samples from nulliparous singleton pregnancies that had no history of chronic hypertension. The two groups (normal and lateonset preeclampsia) were not significantly different in maternal age, maternal body mass index, fetal birthweight or gestation at delivery.
Serum levels of GDF15 increase with gestational age
We first investigated whether the circulating levels of GDF15 are associated with gestational age in normotensive pregnant women. We determined GDF15 levels in sera collected in the first (11-13 weeks, n=9), second (23-27 weeks, n=9) and third (33- Serum GDF15 is significantly reduced in preeclampsia at disease presentation 9 We next compared serum levels of GDF15 in the third trimester from women who were presenting with preeclampsia and who were normotensive. The levels of GDF15 were significantly lower in women with preeclampsia (20560±37362 pg/ml, n=34) compared with their normotensive counterparts (59776±33858 pg/ml, n=66) (p=0.001).
We further investigated whether serum GDF15 alterations were associated with the timing of preeclampsia onset. When the preeclampsia samples were separated into early-onset (<34 weeks, n=16) and late-onset (>34 weeks, n=18) subtypes, GDF15 levels were still significantly lower in preeclampsia compared to their respective normotensive controls (<34 weeks, n=20; >34 weeks, n=46, Figure 2 ). However, it's notable that the reduction was more drastic and consistent for the late-onset than the early-onset subtype compared to their respective controls (Figure 2 , early-onset, p=0.001; late-onset, p=0.0001).
As the difference in serum GDF15 was more pronounced for late-onset preeclampsia, we performed a receiver operating characteristic (ROC) analysis ( Figure 3 ) for this sub-type (n=18) and their respective control samples (n=46) presented in Figure 2 The area under the ROC curve was 0.91 (p<0.0001); at a cutoff of <37567pg/ml, the specificity was 96% and sensitivity was 89%.
First trimester serum GDF15 is not altered in women destined to develop late-onset preeclampsia
We further investigated whether serum GDF15 is altered in the first trimester in women who are destined to develop late-onset preeclampsia in the third trimester. We screened for GDF15 in a total of 69 maternal sera collected at 11-13 weeks of gestation from women who later developed late-onset preeclampsia (n=36) or proceeded with normal pregnancies (n=33).
The two groups showed very similar levels of serum GDF15 (Figure 4 , p=0.79), indicating 10 that first trimester serum GDF15 has no predictive value for later development of preeclampsia.
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Discussion
GDF15 was initially isolated from activated human macrophages in 1997 [24] and subsequently shown to be highly expressed in the placenta [25, 26] . GDF15 is expressed in trophoblast cell columns that will differentiate into invasive extravillous trophoblast (EVT) [19] , it is also expressed in the syncytiotrophoblast throughout pregnancy [19] . The circulating levels of GDF15 increase dramatically during early pregnancy, and the levels at 10-14 weeks of gestation are 15-fold higher in comparison to the non-pregnant state [27] .
Lower levels of GDF15 in the first trimester are associated with miscarriage [28] . These data suggest that GDF15 may play important physiological roles in placental development and function. However, it remains unclear whether the circulating levels of GDF15 are altered in preeclampsia at the time of or prior to disease presentation.
In this study, we showed that the serum levels of GDF15 increased significantly with increasing gestation, reaching the highest level in the 3 rd trimester (33-40 weeks of gestation).
We also found that the serum levels of GDF15 in the third trimester were significantly lower in women presenting with preeclampsia. A significant reduction in serum GDF15 was seen in late-onset as well as early-onset preeclampsia subtypes, but the reduction was more profound in late-onset cases. We thus further investigated whether serum GDF15 in the first trimester could predict later development of late-onset preeclampsia, however, no difference was found in serum GDF15 at 11-13 weeks of gestation between women who later developed late-onset preeclampsia and who had uncomplicated pregnancies.
The increase in circulating levels of GDF15 during pregnancy is attributed to placental expression [29] . In addition, because iron regulates the secretion of GDF15 [30] and iron absorption is increased during pregnancy [31] , iron regulation may also contribute to the observed GDF15 serum changes in pregnancy. A previous study reported that the circulating levels of GDF15 peaked at 33-35 weeks of gestation [19] , this is consistent with our observation that serum GDF15 increased with gestation and that the level reached the highest in the third trimester.
In this study, we found that the serum levels of GDF15 were significantly decreased in the third trimester in women presenting with preeclampsia compared to normotensive, and that this GDF15 reduction was not associated with the timing of preeclampsia onset. These results are different from two previous reports [19, 32] . In the study of Marjono et al [19] , no difference in serum levels of GDF15 was found between preeclamptic and control groups in the third trimester. On the other hand, the study of Sugulle et al reported a significant increase in circulating levels of GDF15 in preeclamptic women at term (gestational week ≥ 37)
compared to gestation age-matched normotensive controls [32] . The exact reasons for these differences are unknown; however, differences in sample size, maternal age and ethnicities may be contributing factors. The sample size of preeclampsia in Marjono's and Sugulle' study was 23 and 21 respectively, while our current study had a total of 34 women with preeclampsia. In addition, circulating levels of GDF15 are reported to positively associate with age over 45 years [33, 34] . The median maternal age of our study was 26 (control) and 27 (preeclampsia) respectively, whereas the median maternal age studied by Sugulel et al was 33 (control) and 31 (preeclampsia) years respectively. But the maternal age for the Marjono's subjects was not reported [19] . Another reason could be that we and Marjono et al [19] analyzed serum, whereas plasma was assayed by Sugulle et al [32] . Using plasma vs serum may give different results, as a number of studies indicate that serum may differ from plasma in the detection of preeclampsia [35] . Ethnicity has been suggested to be associated with the pathogenesis of preeclampsia [36, 37] , therefore the ethnicity difference may be a contributing factor to the result discrepancies between our study and that of Sugulle et al [32] .
However, these mentioned differences do not fully explain the observed differences in GDF15 levels, and future studies are needed to address and clarify these.
13 Furthermore, our current study further analyzed preeclampsia into early-onset and late-onset subtypes, which was not considered by the previous two studies [19, 32] . Our data shows that the reduction in serum GDF15 was more severe in late-onset than early-onset cases, highlighting that the two preeclampsia subtypes are distinct.
Future studies need to investigate whether a reduction in serum GDF15 contributes to the development of preeclampsia, or it is a maternal response to preeclampsia. However, we found no difference in serum GDF15 levels at 11-13 weeks of gestation between women who later developed late-onset preeclampsia and who did not. This data suggests that serum GDF15 may not influence the causes of preeclampsia development. It's likely that the reduction in serum GDF15 seen at the time of preeclampsia presentation is due to maternal response to the disease. Although we were not able to assess whether serum levels of GDF15
in first trimester are altered in women who later develop early-onset preeclampsia, our study does not suggest that the first trimester serum GDF15 will be useful to predict future development of late-onset preeclampsia. However, it will be interesting to determine whether GDF15 levels in second trimester would be useful to predict future development of preeclampsia.
In conclusion, we demonstrated that in normal pregnancy the circulating levels of GDF15 increased with gestational age and that the GDF15 level was highest in 3 rd trimester. We also found that serum levels of GDF15 were significantly reduced in women presenting with preeclampsia in the third trimester, and that this reduction was more profound in late-onset than early-onset cases. However, serum GDF15 was not altered at 11-13 weeks of gestation in women who later developed late-onset preeclampsia. and Post-hoc test were performed. 
